Microport Scientific Aims To Expand Product Portfolio

, , Leave a comment

MicroPort Scientific India this week claimed that it is seeking to expand vertically and horizontally in terms of product portfolios as well as growth around the country. It is an Indian arm of MicroPort Scientific Corporation, the medical device company located in Shanghai.

“We will be growing vertically and horizontally in terms of product portfolios as well as expansion across the country. Our worldwide leadership has extremely healthy expansion plans for the country. We have a solid commitment from the organization to introduce investment needed to attain our quick sustainable development,” Riyaz Desai, Managing Director, MicroPort Scientific India said to the media in a statement.

Microport Scientific Aims To Expand Product Portfolio

The firm offers medical solutions wrapping 10 main disciplines comprising orthopedics, interventional cardiology, neurovascular, endovascular, diabetes, electrophysiology, surgical management, endocrine management, and others. Desai gave this data to the media in a statement.

The firm has FireHawk, the pioneering Target Eluting Stent (TES) technology product. It is eyeing at almost 20% share in the market in the stent industry. “Our TES proposes that the curing time is less than other Drug Eluting Stents (DES),” he further added while talking to the media.

Speaking on the latest cost regulation by NPPA of cardio vascular stents, Desai claimed that the firm is totally aligned with mission of the government to provide reasonably priced healthcare. “While most of the companies are being obliged by the government to provide their new technologies, we are willingly entering the industry and giving our best at the regulated cost in the class technology.

“This will have deep impact as more patients and doctors will select this technology and surely can have enhanced outcomes related to long-term clinical. We have several other product portfolios in different areas of therapeutic such as neurovascular, orthopedic, electrophysiology, and peripheral vascular and they will be rolled out soon in the country,” Desai claimed to the media in a statement.

The short-term investment of the company might be in education and people. In long term, it is also discovering chances to have domestic partners and manufacturers with the government in “Make in India” proposals, he further added while addressing to the media.

 

Leave a Reply